Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Hypertension. 2007;50:945-951
Published online before print October 1, 2007, doi: 10.1161/HYPERTENSIONAHA.107.094268
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
50/5/945    most recent
HYPERTENSIONAHA.107.094268v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tordjman, K. M.
Right arrow Articles by Stern, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tordjman, K. M.
Right arrow Articles by Stern, N.
Related Collections
Right arrow Pathophysiology
Right arrow Other hypertension
Right arrow Genetically altered mice
Right arrow Hypertension - basic studies
Right arrow Mechanism of atherosclerosis/growth factors
Right arrowRelated Article

(Hypertension. 2007;50:945.)
© 2007 American Heart Association, Inc.

Original Articles

Absence of Peroxisome Proliferator-Activated Receptor-{alpha} Abolishes Hypertension and Attenuates Atherosclerosis in the Tsukuba Hypertensive Mouse

Karen M. Tordjman; Clay F. Semenkovich; Trey Coleman; Rachel Yudovich; Stella Bak; Etty Osher; Michal Vechoropoulos; Naftali Stern

From the Institute of Endocrinology, Metabolism and Hypertension (K.M.T., R.Y., E.O., M.V., N.S.) and Department of Pathology and Cancer Research (S.B.), Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel; and the Division of Endocrinology, Metabolism, and Lipid Research (C.F.S., T.C.), Departments of Medicine, Cell Biology, and Physiology, Washington University School of Medicine, St Louis, Mo.

Correspondence to Karen M. Tordjman, Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel. E-mail karentor{at}tasmc.health.gov.il

Peroxisome proliferator-activated receptor-{alpha} is widely distributed in the vasculature where it is believed to exert pleiotropic antiatherogenic effects. Its role in the regulation of blood pressure is still unresolved; however, some evidence suggests that it may affect the renin-angiotensin system. We investigated its role in angiotensin II–induced hypertension in the Tsukuba hypertensive mouse (THM). This is a model of hypertension and atherosclerosis because of high angiotensin II and aldosterone levels as a result of the transgenic expression of the entire human renin-angiotensin system. Making the THM animals deficient in Peroxisome proliferator-activated receptor-{alpha} (THM/PPARKO) totally abolished hypertension and myocardial hypertrophy. This was accompanied by a reduction in plasma human active renin in THM/PPARKO mice compared with THM animals from 3525±128 mU/L to 1910±750 mU/L (P<0.05) and by a normalization of serum aldosterone (1.6±0.29 nmol/L versus 3.4±0.69 nmol/L; P=0.003). In the THM/PPARKO mice, the extent of atherosclerosis at the aortic sinus after a 12-week period on an atherogenic diet was decreased by >80%. In addition, the spontaneous formation of foam cells from peritoneal macrophages, a blood pressure–independent event, was reduced by 92% in the THM/PPARKO mice, suggesting protection from the usual oxidative stress in these animals, possibly because of lower prevailing angiotensin II levels. Finally, chronic fenofibrate treatment further elevated blood pressure in THM animals but not in THM/PPARKO animals. Taken together, these data indicate that peroxisome proliferator-activated receptor-{alpha} may regulate the renin-angiotensin system. They raise the possibility that its activation may aggravate hypertension and hasten atherosclerosis in the context of an activated renin-angiotensin system.


Key Words: PPAR{alpha} • renin • angiotensin • hypertension • atherosclerosis • transgenic mice


Related Article:

Peroxisome Proliferator-Activated Receptor–{alpha}: Friend or Foe?
Chana Yagil and Yoram Yagil
Hypertension 2007 50: 847-850. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Diabetes CareHome page
G. T. Chew, G. F. Watts, T. M.E. Davis, B. G.A. Stuckey, L. J. Beilin, P. L. Thompson, V. Burke, and P. J. Currie
Hemodynamic Effects of Fenofibrate and Coenzyme Q10 in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction
Diabetes Care, August 1, 2008; 31(8): 1502 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
I. Kuipers, P. van der Harst, G. Navis, L. van Genne, F. Morello, W. H. van Gilst, D. J. van Veldhuisen, and R. A. de Boer
Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System
Hypertension, June 1, 2008; 51(6): 1442 - 1448.
[Full Text] [PDF]

Home page
 CirculationHome page
P. Gratze, R. Dechend, C. Stocker, J.-K. Park, S. Feldt, E. Shagdarsuren, M. Wellner, F. Gueler, S. Rong, V. Gross, et al.
Novel Role for Inhibitor of Differentiation 2 in the Genesis of Angiotensin II-Induced Hypertension
Circulation, May 20, 2008; 117(20): 2645 - 2656.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Yagil and Y. Yagil
Peroxisome Proliferator-Activated Receptor {alpha}: Friend or Foe?
Hypertension, November 1, 2007; 50(5): 847 - 850.
[Full Text] [PDF]


Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.